Treatment of Serratia marcescens Infections

First-Line Treatment Options

• For Gram-negative bacteria including Serratia marcescens, a combination of an extended-spectrum penicillin (e.g., piperacillin/tazobactam) or an extended-spectrum cephalosporin (e.g., ceftazidime, ceftriaxone, or cefotaxime) together with an aminoglycoside is recommended for a minimum of 6 weeks of therapy, as suggested by the American Heart Association 1

Treatment Based on Infection Site

Endocarditis

• For endocarditis caused by Serratia marcescens, cardiac surgery in combination with prolonged courses of combined antibiotic therapy is a cornerstone of treatment, with valve replacement after 7-10 days of antibiotic therapy recommended, as mortality rates can reach 70% 2
• A combination of a third-generation cephalosporin and an aminoglycoside (either gentamicin or amikacin) is recommended for Gram-negative bacillary endocarditis 2

Skin and Soft Tissue Infections

• For necrotizing soft tissue infections caused by Gram-negative bacteria including Serratia marcescens, broad-spectrum coverage should be urgently commenced, with carbapenems, such as meropenem, imipenem-cilastatin, or doripenem, potentially used in settings with high local prevalence of ESBL-producing Enterobacteriaceae 3

Treatment Duration

• For endocarditis and other serious infections caused by Serratia marcescens, therapy should be administered for a minimum of 6 weeks 1
• Antimicrobial therapy should be continued until further debridement is no longer necessary, the patient has improved clinically, and fever has been resolved for 48-72 hours, with procalcitonin monitoring potentially useful to guide antimicrobial discontinuation in cases of necrotizing infections 3

Monitoring and Follow-up

• Blood cultures should be obtained if systemic symptoms are present to rule out concurrent bacteremia, which would require more aggressive management, as recommended by medical guidelines 4
• Follow-up cultures should be obtained to document clearance of infection, especially in cases of persistent or recurrent infections 4

Treatment of Serratia marcescens Infections

Intra-abdominal Infections

• For complicated intra-abdominal infections, a carbapenem-sparing regimen is preferred where possible, and ceftolozane/tazobactam plus metronidazole may be valuable for treating infections caused by gram-negative MDROs to preserve carbapenems 5

Special Populations

• For neutropenic patients with cancer, S. marcescens is recognized as a potential pathogen, and in vascular catheter-related infections, catheter removal may be required if response to antibiotics is not apparent after 2-3 days of therapy 6

Treatment for Serratia Infections

Initial Empiric Therapy Selection

• For ventilator-associated pneumonia or healthcare-associated infections, the Infectious Diseases Society of America recommends using antipseudomonal agents including cefepime, ceftazidime, piperacillin-tazobactam, imipenem, or meropenem, combined with either an aminoglycoside or fluoroquinolone 7
• For intra-abdominal infections, the Infectious Diseases Society of America suggests fluoroquinolones (ciprofloxacin or levofloxacin) combined with metronidazole are appropriate options, or use ceftolozane/tazobactam plus metronidazole to preserve carbapenems 8

Site-Specific Treatment Recommendations

Central Nervous System Infections

• Meropenem is preferred over imipenem due to lower seizure risk and better CSF penetration, as recommended by the Infectious Diseases Society of America 9

Critical Resistance Considerations

• Serratia species may develop resistance during therapy, and meropenem-containing regimens are preferred for hyperproducing lactamases, according to the Infectious Diseases Society of America 9
• Beware of colistin resistance, as Serratia is intrinsically resistant to colistin, as noted by the Infectious Diseases Society of America 10

Treatment of Persistent Serratia Infection

First-Line Treatment for Persistent Infection

• The Infectious Diseases Society of America recommends piperacillin-tazobactam 4.5g IV every 6 hours for susceptible Serratia isolates, though combination therapy is preferred for serious infections 10
• Fluoroquinolones, such as ciprofloxacin or levofloxacin, can be used for susceptible Serratia in less severe infections or as step-down oral therapy, as suggested by the American Academy of Pediatrics 11 and the Infectious Diseases Society of America 8

Site-Specific Considerations

Intra-abdominal Infections

• The Infectious Diseases Society of America suggests adding metronidazole to fluoroquinolone or cephalosporin regimens for anaerobic coverage in intra-abdominal infections 8

Special Populations

Neutropenic/Immunocompromised Patients

• The Infectious Diseases Society of America recommends broad-spectrum coverage with vancomycin plus an antipseudomonal agent, such as cefepime, carbapenem, or piperacillin-tazobactam, empirically in neutropenic or immunocompromised patients 12

Pediatric Patients

• The American Academy of Pediatrics suggests that fluoroquinolones may be used for susceptible Serratia when other options are limited, though not first-line in children 11
• The Infectious Diseases Society of America also recommends considering fluoroquinolones for susceptible Serratia in pediatric patients 8

Antibiotic Treatment for Serratia marcescens Infections

Intra-abdominal Infections and Bacteremia/Sepsis

• For severe intra-abdominal infections and bacteremia/sepsis, piperacillin-tazobactam or meropenem are recommended 13, 14
• The Infectious Diseases Society of America recommends combination therapy for severe infections, including a third or fourth-generation cephalosporin (ceftazidime or cefepime) plus an aminoglycoside 13, 14

Alternative Agents

• Fluoroquinolones, such as ciprofloxacin, may be used for less severe infections or as step-down oral therapy, but resistance concerns limit their use as first-line agents 13, 14

Antibiotic Treatment for Serratia fonticola Infections

Intra-abdominal Infections

• Ceftriaxone plus metronidazole can be used as an alternative for anaerobic coverage in intra-abdominal infections, according to the Clinical Microbiology and Infection guidelines 15